(a) Bufotenine

     Cannabinol

     Cannabinol derivatives not being dronabinol or its stereoisomers

     Cannabis and cannabis resin

     Cathinone

     Coca leaf

     Concentrate of poppy-straw

     Eticyclidine

     Etryptamine

     Lysergamide

     Lysergide and other N-alkyl derivatives of lysergamide

     Mescaline

     Methcathinone

     Psilocin

     Raw opium

     Rolicyclidine

     Tenocyclidine

     4-Bromo-2,5-dimethoxy-a-methylphenethylamine

     N,N-Diethyltryptamine

     N,N-Dimethyltryptamine

     2,5-Dimethoxy-alpha,4-dimethylphenethylamine

     N-Hydroxy-tenamphetamine

     4-Methyl-aminorex

(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c) the following phenethylamine derivatives, namely - 

[erowid note: erowid has added our guesses at the PiHKAL names for the following phenethylamines, but this is a first stab at this and we are not 100% positive about all the IDs, so corrections are welcome]

     Allyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDAL, PiHKAL 101]

     2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol [erowid: aka BOHD, PiHKAL 16]

     2-Amino-1-(3,4-dimethoxyphenyl)ethanol [erowid: aka DME, PiHKAL 57]

     Benzyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDBZ, PiHKAL 103]

     4-Bromo-ß,2,5-trimethoxyphenethylamine [erowid: aka BOB, PiHKAL 13]

     N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine [erowid: aka HOT-17, PiHKAL 89]

     Cyclopropylmethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDCPM, PiHKAL 104]

     2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine [erowid: aka 2C-G-3, PiHKAL 28 -- If this was what was meant by the British, there is an error on their part. An indane is a 2,3-dihydroindene so there cannot be such a thing as a 2,3-dihydro-indane. The name they probably intended to use was: 2-(4,7-Dimethoxy-2,3-dihydro-1H-inden-5-yl)ethylamine]

     2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine [erowid: aka G-3, PiHKAL 82 - Exactly the same error as was made in their attempt to list PiHKAL #28, presented in the entry immediately above this one. As written, it makes no sense. What was intended, surely, was: 2-(4,7-Dimethoxy-2,3-dihydro-1H-inden-5-yl)-1-methylethylamine]

     2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine [erowid: aka DMCPA, PiHKAL 56]

     2-(1,4-Dimethoxy-2-naphthyl)ethylamine [erowid: aka 2C-G-N, PiHKAL 31]

     2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine [erowid: aka G-N, PiHKAL 86]

     N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine [erowid: aka HOT-7, PiHKAL 88]

     2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine [erowid: AKA 2C-G-4, PiHKAL 29]

     2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine [erowid: aka G-4, PiHKAL 83]

     alpha, alpha-Dimethyl-3,4-methylenedioxyphenethylamine [erowid: aka MDPH, PiHKAL 116]

     alpha, alpha-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine [erowid: aka MDMP, PiHKAL 113 ]

     Dimethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDDM, PiHKAL 105]

     N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine [erowid: aka HOT-2, PiHKAL 87]

     4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine [erowid: aka IDNNA , PiHKAL 90]

     2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine [erowid: aka 2C-G-5, PiHKAL 30]

     2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine [erowid: aka G-5, PiHKAL 84]

     2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine [erowid: aka F-22, PiHKAL 80]

     2-Methoxyethyl(alpha-methyl-3,4-methylenedioxyphenethyl)amine [erowid: aka MDMEOET, PiHKAL 112]

     2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine [erowid: aka F-2, PiHKAL 79]

     ß-Methoxy-3,4-methylenedioxyphenethylamine [erowid: aka BOH, PiHKAL 15]

     1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine [erowid: Ethyl-K, thanks to N]

     1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine [erowid: Methyl-K, thanks to N]

     2-(alpha-Methyl-3,4-methylenedioxyphenethylamino)ethanol [erowid: aka MDHOET, PiHKAL 107]

     alpha-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine [erowid: aka MDPL, PiHKAL 117]

     N-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl)hydroxylamine [erowid: aka FLEA, PiHKAL 81]

     O-Methyl-N-(alpha-methyl-3,4-methylenedioxyphenethyl)hydroxylamine [erowid: aka MDMEO, PiHKAL 111]

     alpha-Methyl-4-(methylthio)phenethylamine [erowid: not found in PiKHAL by me .. analog of 4-MA ; probly not as evil to schedule given 4-MA's toxicity. 2C-T without the 2,5diMeO part. -- Early reports of it were dated 1998, in DEA's Microgram Vol. 31, May, page 150 and June page 174. The initial pharmacological studies were by David Nichols, see European J. Pharm. Vol. 229 pp 31-38 (1992). The British seized some 25,000 tablets (called "Flatliners") which were analyzed as being 4-MTA by the London Toxicology Group.]

     ß,3,4,5-Tetramethoxyphenethylamine [erowid: aka BOM, PiHKAL 17]

     ß,2,5-Trimethoxy-4-methylphenethylamine [erowid: aka BOD, PiHKAL 14]

(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, alpha-methylphenethylamine, an N-alkyl-alpha-methylphenethylamine, alpha-ethylphenethylamine, or an N-alkyl-alpha-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -


(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi) by replacement of the N-propionyl group by another acyl group;



(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say - 



(i) by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v) by formation of an N-oxide or of a quaternary base.

     2. Any stereoisomeric form of a substance specified in paragraph 1.

     3. Any ester or ether of a substance specified in paragraph 1 or 2.

     4. Any salt of a substance specified in any of paragraphs 1 to 3.

     5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.

(a)

(b) any 5, 5 disubstituted barbituric acid not being quinalbarbitone.

     2. Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.

     3. Any salt of a substance specified in paragraph 1 or 2.

     4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

(a) by further substitution at position 17 by a methyl or ethyl group;

(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

(c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

(d) by fusion of ring A with a heterocyclic system.

     3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.

     4. The following substances, namely - 

Chorionic Gonadotrophin (HCG)

Clenbuterol

Non-human chorionic gonadotrophin

Somatotropin

Somatrem

Somatropin

     5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.

     6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.

     7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.

10% opium, in powder,

10% ipecacuanha root, in powder, well mixed with

80% of any other powdered ingredient containing no controlled drug.

     9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.